Argenx has decided not to go ahead with its development plans for efgartigimod as a potential treatment for…
Articles by Margarida Maia, PhD
Amgen is planning to launch a Phase 3 clinical trial testing Tavneos (avacopan) — its approved therapy for adults…
Sinonasal symptoms, as assessed with 22-item Sinonasal Outcome Test (SNOT-22), a patient-reported questionnaire, are more severe when ANCA-associated vasculitis…
Patrys’ PAT-DX1 and PAT-DX3, two DNA-targeting antibodies known as deoxymabs, can suppress production of the antimicrobial webs implicated in…
Having microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) — the two most common types of ANCA-associated vasculitis (AAV)…
ANCA-associated vasculitis (AAV) patients receiving a cumulative dose of at least 935 mg of glucocorticoids over six months are…
Recruitment is continuing in three countries for a Phase 1b/2a clinical trial testing Alpine Immune Sciences’ povetacicept in adults…
The Renal Risk Score may be a better histopathologic classification model than Berden for predicting long-term loss of kidney function…
The Kidney Disease: Improving Global Outcomes (KDIGO) work group has released an updated practice guideline based on developments…
Tavneos (avacopan) improved kidney function and reduced the need for the glucocorticoid prednisone in four older patients who had…